Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

BACKGROUND: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS CoV-2 infection and related severe COVID-19. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Parienti, Jean-Jacques, Prazuck, Thierry, Peyro-Saint-Paul, Laure, Fournier, Anna, Valentin, Cécile, Brucato, Sylvie, Verdon, Renaud, Sève, Aymeric, Colin, Mathilda, Lesne, Fabien, Guinard, Jérome, Ar Gouilh, Meriadeg, Dina, Julia, Vabret, Astrid, Hocqueloux, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235994/
https://www.ncbi.nlm.nih.gov/pubmed/34222849
http://dx.doi.org/10.1016/j.eclinm.2021.100993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235994/
https://www.ncbi.nlm.nih.gov/pubmed/34222849
http://dx.doi.org/10.1016/j.eclinm.2021.100993

Ejemplares similares